Jun. 2 at 11:45 PM
$PFE 5/29/26
In the context of the CROWN trial, "median progression-free survival not reached" means the cancer treatment is so effective that more than half of the patients taking the drug have not had their cancer get worse or died during the seven years of the study.This statistic signifies unprecedented long-term efficacy and highlights the following key details.
In the Phase 3 CROWN trial for advanced ALK-positive non-small cell lung cancer, patients taking Lorbrena had a 55% likelihood of remaining alive and without disease progression at the seven-year mark.
Comparison: By contrast, patients taking the older standard treatment (Xalkori) had a median progression-free survival of just months, with only 3% remaining disease-free at the seven-year mark.
(This info was gathered by AI)
